Dyadic International receives Nasdaq deficiency notice

Dyadic International Inc. (NASDAQ: DYAI) received a deficiency notice from Nasdaq on December 19, 2024, for failing to maintain the minimum $1 per share bid price requirement for 30 consecutive business days.

The biotechnology company has until June 17, 2025, to regain compliance by closing at $1 per share or higher for at least 10 consecutive business days. The notice does not immediately affect the company's listing on the Nasdaq Capital Market.

If Dyadic fails to meet the compliance deadline, it may qualify for an additional 180-day extension period, provided it meets other applicable listing standards and notifies Nasdaq of its intent to address the deficiency. The company would need to satisfy market value requirements and other initial listing criteria except the bid price requirement.

Should the company remain non-compliant after the initial compliance period and not qualify for or fail during the extension period, Nasdaq staff would issue a delisting notice. Dyadic would then have the option to appeal the delisting determination to a Nasdaq hearings panel.

The company stated it plans to monitor its stock price and evaluate available options to resolve the deficiency and regain compliance with Nasdaq's minimum bid price requirement.

You May Also Be Interested In

• Boeing names Ryan Shedd as new SVP and controller
• Baiya International Group (BIYA) files $200M mixed shelf
• loanDepot receives NYSE non-compliance notice over stock price